文献速递外周动脉疾病

主髂动脉闭塞性疾病:腔内髂动脉支架与开放主双股旁路的中期结局比较

Endovascular Iliac Stenting versus Open Aortobifemoral Bypass for Aortoiliac Occlusive Disease: A Retrospective Multicentre Cohort Study.
PubMed 文献 · Ann Vasc Surg · 2026-10-14

多中心回顾性队列研究纳入171例主髂动脉闭塞性疾病患者,比较腔内治疗与开放旁路的疗效。腔内组24个月一期通畅率62.7%低于开放组91.8%(IPTW校正HR 5.67),但两组保肢生存率和总生存率无差异。结论支持风险分层选择治疗,而非统一腔内优先。

要点

  • 开放旁路中期通畅率显著优于腔内治疗,TASC D和CLTI亚组差异最明显。
  • 两组截肢-free生存和总生存无差异,伤口感染腔内组更低。
  • 主要截肢独立预测因素为CLTI表现和年龄,而非治疗方式。

核心结论

  • 开放旁路较腔内重建在主髂动脉闭塞性疾病中提供显著的中期通畅率和免再干预生存优势。
  • 该优势在TASC D和CLTI亚组中最明显,但保肢和生存无相应差异。

研究设计与样本

  • 回顾性非随机多中心队列研究,纳入171例Rutherford 3-6的主髂动脉闭塞性疾病患者。
  • 患者来自英国、爱尔兰和埃及三个中心,治疗时间2023年1月至2026年2月。
  • 采用Cox回归和IPTW校正治疗选择偏倚。

主要发现

  • 125例(73.1%)接受腔内治疗,46例(26.9%)接受开放旁路。
  • 腔内组年龄更大(66.8 vs 60.8岁,p<0.001),TASC C-D病变比例更低(53.6% vs 93.5%,p<0.001)。
  • 24个月一期通畅率62.7% vs 91.8%(log-rank p<0.001;IPTW校正HR 5.67,95%CI 1.75-18.37)。
  • 24个月免再干预率63.1% vs 93.3%(p<0.001)。
  • 伤口感染腔内组更低(0.8% vs 10.9%,p=0.006)。

关键数值与推荐

  • 24个月一期通畅率:腔内组62.7%,开放组91.8%。
  • 24个月免再干预率:腔内组63.1%,开放组93.3%。
  • IPTW校正HR 5.67(95%CI 1.75-18.37)支持开放旁路。
  • 主要截肢独立预测因素:CLTI表现(OR 4.0)和年龄,非治疗组。

临床怎么用

  • 对于TASC D和CLTI患者,开放旁路可能提供更好的中期通畅,应风险分层选择而非统一腔内优先。
  • 腔内治疗可减少伤口感染,但需权衡再干预风险。
  • 截肢风险主要与CLTI和年龄相关,需关注远端病变进展。

局限性

  • 回顾性非随机设计,存在选择偏倚,尽管采用IPTW校正。
  • 样本量较小(171例),开放组仅46例。
  • 随访时间有限,中期结果需长期验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortoiliac occlusive disease (AIOD) causing chronic or critical limb-threatening ischaemia can be treated by open aortobifemoral bypass (ABF) or endovascular reconstruction. Comparative-effectiveness data adjusted for treatment-selection bias remain limited. This multicentre study compared mid-term outcomes of endovascular versus open reconstruction for AIOD. METHODS: Retrospective, non-randomised cohort study of 171 patients with AIOD (Rutherford 3-6) treated at three centres (UK, Ireland, Egypt) between January 2023 and February 2026. Outcomes were primary patency, freedom from reintervention (FFR), amputation-free survival (AFS), overall survival, and perioperative complications. Cox regression and inverse-probability-of-treatment weighting (IPTW) were used to adjust for confounding. RESULTS: 125 patients (73.1%) underwent endovascular treatment and 46 (26.9%) open bypass. Endovascular patients were older (66.8 vs 60.8 years, p<0.001) and had a lower burden of TASC C-D disease (53.6% vs 93.5%, p<0.001). Primary patency at 24 months was 62.7% vs 91.8% (log-rank p<0.001; IPTW-adjusted HR 5.67, 95% CI 1.75-18.37). Freedom from reintervention at 24 months was 63.1% vs 93.3% (p<0.001). Amputation-free survival (85.0% vs 87.4%, p=0.992) and overall survival (93.3% vs 90.0%, p=0.335) were comparable between groups. Wound infection was less frequent after endovascular treatment (0.8% vs 10.9%, p=0.006). Major amputation was independently predicted by CLTI presentation (OR 4.0) and age, not treatment group. Progressive infrainguinal disease, rather than failure of proximal revascularisation, accounted for most amputations in both groups. CONCLUSION: Open bypass confers a substantial mid-term patency and reintervention-free survival advantage over endovascular reconstruction for AIOD, most pronounced in TASC D and CLTI subgroups, without a corresponding difference in limb salvage or survival. These findings support risk-stratified rather than uniformly endovascular-first treatment selection, pending confirmation from the ongoing EVOCC randomised trial.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Elmetwally A, Morshed AM, Meselhi A, et al. Endovascular Iliac Stenting versus Open Aortobifemoral Bypass for Aortoiliac Occlusive Disease: A Retrospective Multicentre Cohort Study. Ann Vasc Surg. 2026. PMID: 42874862. doi:10.1016/j.avsg.2026.09.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。